Welcome to our dedicated page for American Fusion news (Ticker: AMFN), a resource for investors and traders seeking the latest updates and insights on American Fusion stock.
American Fusion Inc. reports company developments tied to its Texatron fusion energy platform, including pre-production assembly readiness, component integration, diagnostic and testing support, and related working-capital needs. News also covers corporate actions involving the company's authorized-share structure, common-share base, financing arrangements, governance updates, and operating results.
American Fusion news also includes activity from its Government Procurement Services segment, which is positioned separately from the company's core fusion development activities. That coverage centers on government and institutional procurement work, source-of-supply vendor activity, and the company's broader public-company transition under the AMFN symbol.
American Fusion (OTC:AMFN) reported arrival of its team in the Midland-Odessa region to accept delivery of a 5MW Pre-Production Texatron™ Fusion Engine™. The system will be moved to the Dallas-Fort Worth area for installation, commissioning, and integrated testing.
The 5MW platform follows nine prototype generations and is expected to be the main testbed for aneutronic fusion development. American Fusion has sufficient Deuterium and Helium-3 for anticipated tests through 2026 and is exploring future 10MW and 20MW systems, while expanding IP and regulatory initiatives.
American Fusion (OTC: AMFN) appointed physicist Dr. Robert V. Duncan as Independent Scientific and Strategic Advisor. Duncan is President’s Distinguished Chair in Physics at Texas Tech University and has held senior roles at Sandia, Los Alamos-related programs, and major research universities.
According to American Fusion, he will advise on development and testing of the Texatron Fusion Engine, intellectual property strategy, commercialization planning, government and national laboratory engagement, corporate governance, and long-term fusion deployment strategies, reinforcing the company’s focus on rigorous scientific development.
American Fusion (OTC:AMFN) announced that CTO Dr. John Brandenburg has been invited to present the company’s Texatron™ Fusion Engine™ technology at the IEEE ICOPS 2026 conference starting June 22, 2026.
The talk will cover the Texatron platform’s history, technical approach, compact design, and potential use in distributed power generation.
American Fusion (OTC: AMFN) filed U.S. Patent Application No. 19/701,742 on June 10, 2026 for a novel Texatron™ Fusion Engine™ system architecture supporting plasma confinement, pulsed energy delivery, and future deployment. The company reports progress on its 5MW Pre-Production Texatron program, including frame completion, final fabrication in Midland/Odessa, Texas, and ongoing regulatory review of its February 27, 2026 certification application with Texas DSHS. Management expects near-term delivery for future testing in the Dallas-Fort Worth area and highlights continued IP expansion, regulatory advancement, and commercialization planning.
American Fusion (OTC: AMFN) outlined development and testing plans for its 5MW Pre-Production Texatron™ Fusion Engine™. Final modifications are nearly complete, with delivery to the DFW facility expected next week.
The company detailed a five-phase roadmap through integrated fusion testing and independent validation, targeting completion by August 2026, subject to regulatory approvals, equipment timelines, capital availability, and test success. American Fusion is progressing DSHS certification, building a testing bunker, acquiring diagnostic instrumentation, and securing Deuterium and Helium‑3 fuel for testing through 2026. Corporate updates include advancing 15c2‑11 and OTCQB applications, ongoing patent filings, approximately $1.1 million in recent capital raised, a non-binding PPA LOI for up to 20MW, and efforts to reduce a legacy judgment.
American Fusion (OTC: AMFN) filed a new patent application covering innovations and design features for future commercial Texatron™ Fusion Engine™ systems, following Version 9 testing. Management views this as part of a long-term commercialization strategy and believes disclosed innovations may ultimately support about 300 additional patent filings.
American Fusion (OTC: AMFN) filed its first Form 10‑Q post-Kepler reverse merger, reporting Q1 2026 consolidated results and explaining reverse recapitalization accounting.
Q1 highlights include $99,594 cash, $632,583 operating expenses, a $669,750 net loss, a reduced $9.6M accumulated deficit, major share cancellations, and ongoing Texatron™ Fusion Engine™ prototype and listing initiatives.
American Fusion (OTC: AMFN) released an executive interview outlining progress toward commercializing its Texatron™ Fusion Engine™ platform.
The company has completed its ninth, 0.5-megawatt prototype and is building a five-megawatt pre-production unit, is in late-stage regulatory certification in Texas, and reports growing interest from U.S. military and Canadian defense and space agencies, including a letter of intent for a 20-megawatt project in Northern Canada.
American Fusion (OTC: AMFN) reported progress on its Texatron™ Fusion Engine™ and capital markets initiatives. The company completed the structural frame for a 5MW pre-production unit in Texas and is preparing for integrated testing.
It also expanded engagement with U.S. defense and energy stakeholders, advanced Rule 15c2-11 and Frankfurt quotation applications, expects Form 10 effectiveness around May 15, 2026, is pursuing OTCQB eligibility, and is considering a potential stock dividend.
American Fusion (OTC: AMFN) completed the structural frame for its 5MW Texatron pre-production unit, marking a move from prototype work toward integrated assembly and controlled testing readiness.
The unit will undergo further integration before shipment to Fort Worth for testing, pending regulatory review by the Texas Department of State Health Services. The company engaged Revere Securities as a finder for a proposed $5.0 million offering to fund integration, diagnostics procurement, regulatory and testing activities, and working capital.